---
title: "Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290605129.md"
description: "Atrium Therapeutics announced inducement grants under Nasdaq Listing Rule 5635(c)(4) for eight newly hired non-executive employees. The awards include non-qualified stock options for 66,000 shares at $12.66 per share and restricted stock units for 33,000 shares. These grants were made outside stockholder-approved plans to induce employment, approved by the Board's Human Capital Management Committee."
datetime: "2026-06-23T20:07:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290605129.md)
  - [en](https://longbridge.com/en/news/290605129.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290605129.md)
---

# Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

San Diego - On June 23, 2026, Atrium Therapeutics, Inc. (Nasdaq: RNA) disclosed the offering of inducement grants on June 20, 2026 under the Company's 2026 Employment Inducement Incentive Award Plan (2026 Inducement Plan) as a significant inducement to attract...

### Related Stocks

- [RNA.US](https://longbridge.com/en/quote/RNA.US.md)

## Related News & Research

- [Avidity Biosciences (NASDAQ:RNA) Issues Earnings Results](https://longbridge.com/en/news/295865390.md)
- [Atrium Therapeutics gets FDA IND clearance for ATR 1072, Corventis Phase 1/2 trial to start](https://longbridge.com/en/news/292678130.md)
- [Atrium Therapeutics Reports Second Quarter 2026 Financial Results | RNA Stock News](https://longbridge.com/en/news/295845541.md)
- [18:16 ETInnorna für den „Prix Galien USA Best Startup Award" 2026 nominiert](https://longbridge.com/en/news/295854094.md)
- [Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy | AKTX Stock News](https://longbridge.com/en/news/296232130.md)